

**4 December 2019**

---

**Dementia and Aged Care Services (DACS) grant funding contract for national trial of PainChek® signed**

We are delighted to confirm the \$5M PainChek® national trial grant agreement, which was announced by the Morrison Federal Government on 29<sup>th</sup> April 2019, has now been signed between the Commonwealth represented by Department of Health and PainChek Ltd.

The purpose of the grant is to conduct a national trial of a pain identification smart-phone application (PainChek®) for Australians with dementia living in residential aged care facilities.

The objectives of the grant are to:

1. provide access to PainChek® to people living with dementia in residential aged care;
2. collect relevant data on the use of PainChek® in practice; and
3. evaluate the efficacy of PainChek® to improve the diagnosis and management of pain, quality of life, and/or health outcomes in people living with dementia in residential aged care.

The intended outcome of the grant is to improve diagnosis and management of pain in people living with dementia in residential aged care.

The \$5M grant comprises of:

- a \$500K payment on execution of the agreement to support the development of training materials and an evaluation report.
- \$4.4M for the provision of 100,000 PainChek® licenses for people living with dementia across Residential Aged Care in Australia and;
- \$100K payment for the delivery of an evaluation report at the end of the contract term.

PainChek Ltd commenced the enrolment of Residential Aged Facilities into the Government grant from September 2019, post finalisation of the terms and conditions and internal sign off within the Department of Health. The agreement term ends on 31<sup>st</sup> December 2020.

PainChek Ltd want to take this opportunity to thank the Morrison Government for supporting this key aged care initiative and Minister Ken Wyatt, Minister Richard Colbeck and the Department of Health for their leadership and ongoing support.

## About the Dementia and Aged Care Services (DACS) Fund:

The DACS Fund is designed to better support activities that respond to existing and emerging challenges including dementia care, better support services targeting people from diverse social and cultural backgrounds, and support special measures for Aboriginal and Torres Strait Islander people. The Fund can also be used to support activities that assist the Commonwealth in informing itself about aged care.

## Recent developments at PainChek®

The PainChek® Adult App is clinically validated<sup>1</sup> and regulatory-cleared<sup>2</sup> technology that uses automated facial recognition and analysis to identify, quantify and monitor pain in adults that are unable to verbalise their pain.

The PainChek® Adult App is now in clinical use in more than 260 residential aged care homes across Australia helping to better assess pain severity levels for residents living with dementia and cognitive impairment. Earlier this year, the Australian Federal Government announced it will invest A\$5M to facilitate the implementation of the company's pain recognition app in Australian Aged Care Facilities<sup>3</sup>.

PainChek® has also announced it will be collaborating with Murdoch Children's Research Institute (MCRI), to clinically test a version of the PainChek® App for infants<sup>4</sup>.

The PainChek® Infant *PainFaces* study will be led by Professor Franz Babl (MCRI) and Associate Professor Di Crellin (MCRI) in the Emergency Department (ED) of the Royal Children's Hospital, Melbourne. Lead researcher on the project Associate Professor Crellin has recently evaluated the validity and reliability of two observational children's pain assessment tools, the Face, Legs, Activity, Cries and Consolability (FLACC) scale and the Modified Behavioural Pain Scale (MBPS), in assessing procedural pain in the ED.

In this new study, which is expected to commence later this month, the pain scores derived using the PainChek® Infant App will be compared to those obtained using the FLACC by two independent assessors in approx. 100 infants undergoing painful procedures within the ED.

The Company has also entered the United Kingdom market through a distribution agreement with leading Aged Care software provider Person Centred Software<sup>5</sup> and to date, has successfully commercialised the PainChek® Adult App in Australia, Singapore, New Zealand and UK.<sup>6</sup>

---

1. Atee M, Hoti K, Hughes JD. A Technical Note on the PainChek™ System: A Web Portal and Mobile Medical Device for Assessing Pain in People With Dementia. *Front Aging Neurosci.* 2018 Jun 12;10:117. doi: 10.3389/fnagi.2018.00117. eCollection 2018.

2 PainChek® Adult App has TGA and CE Mark regulatory clearances as a Class 1 Medical Device

3 ASX release dated 29 April 2019

4 ASX announcements dated 2<sup>nd</sup> July

5 ASX release dated 27 May 2019

6. ASX releases dated 6<sup>th</sup> August 2019, 26<sup>th</sup> November 2019, 3<sup>rd</sup> December 2019.

## Ends

This release is authorised by Philip Daffas, Managing Director & CEO.

For further information please contact:

Ian Hobson  
Company Secretary  
Tel: +61 8 9388 8290

Philip Daffas  
Managing Director  
Tel: +61 406-537-235

[www.painchek.com](http://www.painchek.com)

### About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.


PainChek® is a smart-phone based medical device using artificial intelligence to assess and score pain levels in real time and update medical records in the cloud. PainChek® records a short video of the person's face and analyses the images that indicate pain and records them.

Next, the caregiver uses PainChek® to record their observations of other pain related behaviours that complete the assessment. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to monitor the effect of medication and treatment over time.


PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for Children who have not yet learnt to speak.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit [www.painchek.com](http://www.painchek.com)



PainChek® artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain.



PainChek® domains of pain assessment that calculates pain severity score.